Figure 2

Mean (SD) State Trait Anxiety Inventory scores across time at baseline, primary endpoint (one-month post second blinded experimental session), end of stage 1 (one month post third MDMA session, i.e. treatment exit for MDMA 125 mg group), secondary endpoint (one month post second open-label session), end of stage 2 (one month post third open-label session, i.e. treatment exit for control group), 6-month follow-up, and 12-month follow-up. The grey box represents the open-label crossover after placebo group was unblinded at the primary endpoint. Groups were collapsed for long-term follow-ups since all participants had received active doses of MDMA in either the blinded or open-label stage